Skeletal muscle is a critical site of disrupted lipid metabolism in male hypogonadism: an in vivo interventional study
Authors:
Open Access
- 22 October 2026
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Abstract
Context: Male hypogonadism is associated with adverse cardiometabolic outcomes; however, tissue-specific metabolic mechanisms underlying this phenotype remain poorly characterized. Metabolomic profiling in hypogonadism to date has been confined to plasma, with limited insights into skeletal muscle. Objective: To characterize the impact of testosterone replacement therapy (TRT) and androgen deprivation therapy (ADT) on the plasma and skeletal muscle metabolome. Design: Parallel prospective interventional studies examined men initiating TRT for organic hypogonadism (n = 15) and ADT for prostate cancer (n = 15). Participants underwent metabolic phenotyping, plasma sampling, and vastus lateralis muscle biopsies pre- and postintervention (6 months TRT and 3 months ADT), with untargeted metabolomic profiling of both tissues at each timepoint. Results: Testosterone replacement therapy significantly increased serum testosterone (P < .001) and muscle mass (P < .05); ADT significantly reduced serum testosterone (P < .001) and muscle mass (P < .05) while simultaneously increasing fat mass (P < .05). Testosterone replacement therapy significantly altered a total of 118 plasma metabolites, reflecting predominant suppression of circulating lipid species, whereas ADT altered only 2. In skeletal muscle, TRT perturbed 89 metabolites and was characterized by expansion of intramuscular lipid species, while ADT altered 109 metabolites, with predominant depletion of intramuscular lipid classes. Following TRT, 8 lipid classes showed divergent responses between plasma and skeletal muscle. In skeletal muscle, 9 lipid classes responded differentially to TRT and ADT, including fatty acids, triacylglycerides, and ceramides. Conclusion: This study provides the first untargeted metabolomic characterization of skeletal muscle in response to androgen manipulation in humans. Distinct plasma and skeletal muscle responses demonstrate tissue-specific regulation that is incompletely captured by plasma profiling alone. These findings highlight skeletal muscle as a key site of androgen-sensitive metabolic regulation, providing evidence for tissue-specific lipid partitioning that may contribute to the cardiometabolic consequences of hypogonadism.Keywords
Funding Information
- HRB Emerging Clinician Scientist (ECSA-2020-001)
- RCSI StAR
- Medical Research Council Canada (MR/X013758/1)
This publication has 57 references indexed in Scilit:
- Skeletal muscle metabolism in health and disease: Mechanisms, interventions, and clinical perspectivesiScience, 2026
- Metabolomic effects of androgen deprivation therapy treatment for prostate cancerCancer Medicine, 2020
- Lipid modulation of skeletal muscle mass and functionJournal of Cachexia, Sarcopenia and Muscle, 2016
- Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissues of the testicular feminised mouseEndocrine, 2016
- Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the MaleCell Metabolism, 2016
- Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actionsCellular and Molecular Life Sciences, 2011
- Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancerThe Prostate, 2010
- Androgens and metabolic syndrome: Lessons from androgen receptor knock out (ARKO) miceThe Journal of Steroid Biochemistry and Molecular Biology, 2008
- Effect of testosterone on lipolysis in human pre-adipocytes from different fat depotsDiabetologia, 2004
- Androgen receptors in hepatocellular carcinoma and surrounding parenchymaGastroenterology, 1985